**Question:** Anticholinesterase that binds only with the anionic site is

A. Donepezil
B. Galantamine
C. Tacrine
D. Neostigmine

**Correct Answer:** B. Galantamine

**Core Concept:**

Anticholinesterase medications are a class of drugs that are used in the treatment of Alzheimer's disease and other forms of dementia to improve cognitive function by increasing the levels of acetylcholine, a neurotransmitter involved in memory and learning. These medications work by inhibiting the enzyme acetylcholinesterase (AChE), which breaks down acetylcholine. The anionic site on AChE is a negatively charged region on the enzyme that binds with the drug molecules.

**Why the Correct Answer is Right:**

Galantamine is an anticholinesterase drug that selectively binds to the anionic site on acetylcholinesterase. This binding leads to the inhibition of AChE, thus preventing the breakdown of acetylcholine and increasing its concentration in the synaptic cleft. This results in improved cognitive function and memory in patients suffering from Alzheimer's disease and related disorders.

**Why Each Wrong Option is Incorrect:**

A. Donepezil: This anticholinesterase drug also binds to the anionic site on acetylcholinesterase, but it has a higher affinity for the catalytic site of the enzyme. Unlike galantamine, donepezil does not have a preferential effect on the anionic site, resulting in less selective inhibition of AChE and potentially more side effects compared to galantamine.

C. Tacrine: Tacrine is another anticholinesterase drug, but it binds to both the anionic site and the catalytic site of acetylcholinesterase. This dual binding leads to a more significant inhibition of AChE, potentially causing more side effects than galantamine or donepezil, and is therefore less commonly used.

D. Neostigmine: Neostigmine is an anticholinesterase drug that binds to the anionic site on acetylcholinesterase, but it is a competitive inhibitor. This means it competes with acetylcholine for the anionic site, leading to a more significant inhibition of AChE compared to galantamine or donepezil, and potentially causing more side effects. Additionally, neostigmine is a prodrug that requires activation by the enzyme butacetylesterase (BChE) to become active, which may limit its effectiveness in cases where BChE activity is decreased.

**Clinical Pearls:**

1. Galantamine is a more selective inhibitor of acetylcholinesterase, which results in fewer side effects compared to other anticholinesterase drugs.
2. Alzheimer's disease patients may have decreased BChE activity, which can affect the efficacy of drugs like neostigmine that rely on BChE activation.

**Why Galantamine is right:**

Galantamine selectively binds to the anionic site on acetylcholinesterase, leading to a more specific and less-